A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 19, Issue 1, 2004, Pages 58-67

  Jones, Roy W ^a   Soininen, Hilkka ^b   Hager, Klaus ^c   Aarsland, Dag ^d   Passmore, Peter ^e   Murthy, Anita ^f   Zhang, Richard ^g   Bahra, Ranbir ^g  

^a St Martin's Hospital   (United Kingdom)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Dept Med Rehab/Geriat Henriette ^*  (Germany)

^d Rogaland Psykiatriske Sykehus   (Norway)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f EISAI INC   (United States)

^g PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Direct comparative trial; Donepezil; Ease of use; Galantamine

Indexed keywords

DONEPEZIL; GALANTAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ANOREXIA; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISABILITY ASSESSMENT FOR DEMENTIA SCALE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; OUTCOMES RESEARCH; PHYSICIAN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SATISFACTION; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CAREGIVERS; CHOLINESTERASE INHIBITORS; COGNITION; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 0842303605     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1038     Document Type: Article

References (25)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Health Disorder, 4th Edition, Revision. (DSM-IV-R). American Psychiatric Association: Washington, DC.
2. Aricept® (Donepezil Hydrochloride Tablets). December 2000, US Package Insert. Eisai Inc., Teaneck, New Jersey, USA.
3. Beach TG, Kuo Y-M, Spiegel K, et al. 2000. The cholinergic deficit coincides with Aβ deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 59: 308-313.
4. Burns A, Rossor M, Hecker J, et al. 1999. The effects of donepezil in Alzheimer's disease - Results from a multionational trial. Dement Geriatr Cogn Disord 10: 237-244.
5. Coyle JT, Price DL, DeLong MR. 1983. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219: 1184-1190.
6. Davies P, Maloney AJF. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403.
7. Feldman H, Gauthier S, Hecker J, et al. 2001a. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57: 613-620.
8. Feldman H, Sauter A, Donald A, et al. 2001b. The disability assessment for dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 15: 89-95.
9. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr 12: 189-198.
10. Giacobini E. 1990. The cholinergic system in Alzheimer's disease. Prog Brain Res 84: 321-332.
11. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force in Alzheimer's disease. Neurology 34: 939-944.
12. Mohs RC. 1994. Adapted from the Modified (by Connor and Schafer) Administration and Scoring Manual for the Alzheimer's Disease Assessment Scale, Revised Edition. Copyright Mount Sinai School of Medicine: New York.
13. Mohs RC, Doody RS, Morris JC, et al. 2001. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481-488.
14. Perry EK, Perry RH, Blessed G, Tomlinson BE. 1977. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1: 189.
15. Raskind MA, Peskind ER, Wessel T, Yuan W. 2000. Galantamine in AD: A 6-month randomized, placeboc-controlled trial with a 6-month extension. Neurology 54: 2261-2268.
16. Reminyl® (Galantamine HBr). March 2001, US Package Insert. Janssen, Titusville, New Jersey, USA.
17. Rogers SL, Friedhoff LT and The Donepezil Study Group. 1996. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 7: 293-303.
18. Rogers SL, Doody RS, Mohs RC, Friedhoff LT and The Donepezil Study Group. 1998a. Donepezil improves cognition and global function in Alheimer's disease: A 15-week, double-blind, placebo-controlled study. Arch Int Med 158: 1021-1031.
19. Rogers SL, Farlow MR, Doody RE, Mohs RC, Friedhoff LT. 1998b. A 24-week, double-blind, placeboc-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145.
20. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
21. Tariot PN, Solomon PR, Morris JC, et al. 2000. A 5-month, randomized, placeboc-controlled trial of galantamine in AD. Neurology 54: 2269-2276.
22. Wilcock GK, Lilienfield S, Gaens E (on behalf of the Galantamine International-1 Study Group). 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial. BMJ 321: 1445-1449.
23. Wilcock G, Howe I, Coles H, et al. 2003. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20: 777-789.
24. Wilkinson DG, Passmore AP, Bullock R, et al. 2002. A multinational, randomized, 12-week comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Prac 56: 441-446.
25. Winblad B, Engedal K, Soininen H, et al. 2001. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495.